Quantitative signal detection for vaccines: Effects of stratification, background and masking on GlaxoSmithKline's spontaneous reports database

Human Vaccines

Volumn 5, Issue 9, 2009, Pages 599-607

  Zeinoun, Ziad ^a   Seifert, Harry ^b   Verstraeten, Thomas ^a  

^a GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

^b GLAXOSMITHKLINE   (United States)

Author keywords

Bayesian; Disproportionality; Safety; Spontaneous reporting; Vaccines

Indexed keywords

VACCINE;

AGE; ARTICLE; BAYES THEOREM; DATA MINING; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; GEOGRAPHIC DISTRIBUTION; QUANTITATIVE ANALYSIS; REFERENCE DATABASE; SENSITIVITY ANALYSIS; SEX DIFFERENCE; SIGNAL DETECTION; VACCINATION REACTION;

EID: 73649129173     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.9216     Document Type: Article

References (27)

1. th Edition 2003. ISBN: 978-0-470-84552-3.
2. Alvarez-Requejo A, Carvajal A, Bégaud B, Moride Y, Vega T, Arias LH. Under-reporting of adverse drug reactions. Estimate based on a spontaneous reporting scheme and a sentinel system. Eur J Clin Pharmacol 1998; 54:483-8.
3. Hazell L, Shakir SA. Under-Reporting of Adverse Drug Reactions: A Systematic Review. Drug Safety 2006; 29:385-96.
4. Verstraeten T, Baughman AL, Cadwell B, Zanardi L, Haber P, Chen RT. Enhancing vaccine safety surveillance: a capture-recapture analysis of intussusception after rotavirus vaccination. Am J Epidemiol 2001; 154:1006-12.
5. Hauben M, Madigan D, Gerrits CM, Walsh L, Van Puijenbroek EP. The role of data mining in pharmacovigilance. Expert Opin Drug Saf 2005; 4:929-48.
6. Bate A, Evans SJ. Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiol Drug Saf 2009.
7. Evans SJ, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf 2001; 10:483-6.
8. Gould AL. Practical pharmacovigilance analysis strategies. Pharmacoepidemiol Drug Saf 2003; 12:559-74.
9. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. Journal of the National Cancer Institute 1959; 22:719-48.
10. Fram D, Almenoff JS, DuMouchel W. Empirical Bayesian data mining for discovering patterns in post-marketing drug safety. Proceedings of the ninth ACM SIGKDD international conference on Knowledge discovery and data mining 2003; 359-68.
11. Hopstadius J, Norén GN, Bate A, Edwards IR. Impact of stratification on adverse drug reaction surveillance. Drug Saf 2008; 31:1035-48.
12. Woo EJ, Ball R, Burwen DR, Braun MM. Effects of stratification on data mining in the US Vaccine Adverse Event Reporting System (VAERS). Drug Saf 2008; 31:667-74.
13. Almenoff J, Tonning JM, Gould AL, Szarfman A, Hauben M, Ouellet-Hellstrom R, et al. Perspectives on the use of data mining in pharmaco-vigilance. Drug Saf 2005; 28:981-1007.
14. Szarfman A, Machado SG, O'Neill RT. Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA's spontaneous reports database. Drug Saf 2002; 25:381-92.
15. Kubota K, Koide D, Hirai T. Comparison of data mining methodologies using Japanese spontaneous reports. Pharmacoepidemiol Drug Saf 2004; 13:387-94. DOI: 10.1002/pds.964.
16. Fitzmaurice G. Confused by confounding? Nutrition 2003; 19:189-91.
17. Hopstadius J, Norén GN, Bate A, Edwards IR. Stratification for spontaneous report databases. Drug Saf 2008; 31:1145-7.
18. Evans SJ. Stratification for spontaneous report databases. Drug Saf 2008; 31:1049-52.
19. DuMouchel W, O'Neill RT, Szarfman A, et al. Bayesian data mining in large frequency tables, with an application to the FDA spontaneous reporting system 1999; 53:177-202.
20. DuMouchel W, Pregibon D. Empirical bayes screening for multi-item associations. Knowledge Discovery and Data Mining 2001; 67-76.
21. Almenoff JS, DuMouchel W, Kindman LA, Yang X, Fram D. Disproportionality analysis using empirical Bayes data mining: a tool for the evaluation of drug interactions in the post-marketing setting. Pharmacoepidemiol Drug Saf 2003; 12:517-21.
22. Rolka H, Bracy D, Russell C, Fram D, Ball R. Using simulation to assess the sensitivity and specificity of a signal detection tool for multidimensional public health surveillance data. Stat Med 2005; 24:551-62.
23. DuMouchel W, Smith ET, Beasley R, Nelson H, Yang X, Fram D, et al. Association of asthma therapy and Churg-Strauss syndrome: an analysis of postmarketing surveillance data. Clin Ther 2004; 26:1092-104.
24. Szarfman A, Tonning JM, Levine JG, Doraiswamy PM. Atypical antipsychotics and pituitary tumors: a pharmacovigilance study. Pharmacotherapy 2006; 26:748-58.
25. Hauben M, Horn S, Reich L. Potential use of data-mining algorithms for the detection of 'surprise' adverse drug reactions. Drug Saf 2007; 30:143-55.
26. Hauben M, Sakaguchi M, Patadia V, M Gerrits C. Hepatitis B vaccination and multiple sclerosis: a data mining perspective. Pharmacoepidemiol Drug Saf 2007; 16:943-5.
27. Banks D, Woo EJ, Burwen DR, Perucci P, Braun MM, Ball R. Comparing data mining methods on the VAERS database. Pharmacoepidemiol Drug Saf 2005; 14:601-9.